Resultados globales: 5 registros encontrados en 0.02 segundos.
Artículos, Encontrados 5 registros
Artículos Encontrados 5 registros  
1.
9 p, 306.4 KB Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer / Élez Fernández, Mª Elena (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Hendlisz, A. (Institut Jules Bordet (Belgium)) ; Delaunoit, T. (Centres Hospitaliers Jolimont (Belgium)) ; Sastre, J. (Hospital Universitario San Carlos) ; Cervantes, A. (Universitat de València. INCLIVA Institut d'Investigació Sanitària) ; Varea, R. (Eli Lilly and Company (Spain)) ; Chao, G. (Eli Lilly and Company (USA)) ; Wallin, J. (Eli Lilly and Company (Suècia)) ; Tabernero Caturla, Josep (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Universitat Autònoma de Barcelona
This single-arm phase II study investigated the EGFR monoclonal antibody necitumumab plus modified FOLFOX6 (mFOLFOX6) in first-line treatment of locally advanced or metastatic colorectal cancer (mCRC). [...]
2016 - 10.1038/bjc.2015.480
British Journal of Cancer, Vol. 114 (February 2016) , p. 372-380  
2.
6 p, 225.1 KB Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer : results of the EXPERT-C trial / Sclafani, F. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Chau, I. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Cunningham, D. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Peckitt, C. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Lampis, A. (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Hahne, J. C. (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Braconi, C. (The Institute of Cancer Research. Division of Cancer Therapeutics (UK)) ; Tabernero Caturla, Josep (Hospital Universitari Vall d'Hebron) ; Glimelius, B. (University of Uppsala. Department of Immunology, Genetics and Pathology (Sweden)) ; Cervantes, A. (Universidad de Valencia. Departamento de Hematología y Oncología Médica) ; Begum, R. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Gonzalez De Castro, D. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Hulkki Wilson, S. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Eltahir, Z. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Wotherspoon, A. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Tait, D. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Brown, G. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Oates, J. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Valeri, N. (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Universitat Autònoma de Barcelona
Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC. [...]
2015 - 10.1093/annonc/mdv285
Annals of Oncology, Vol. 26, Issue 9 (September 2015) , p. 1936-1941  
3.
8 p, 207.5 KB Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS -mutated metastatic colorectal cancer / Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Cervantes, A (Universidad de Valencia. Biomedical Research Institute (INCLIVA)) ; Tabernero Caturla, Josep (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Roselló, S (Universidad de Valencia. Biomedical Research Institute (INCLIVA)) ; Van Cutsem, E (University Hospitals Gasthuisberg and KU Leuven) ; Tejpar, S (University Hospitals Gasthuisberg and KU Leuven) ; Prenen, H (University Hospitals Gasthuisberg and KU Leuven) ; Martinelli, E (Second University of Naples. Department of Experimental and Clinical Medicine) ; Troiani, T (Second University of Naples. Department of Experimental and Clinical Medicine) ; Laffranchi, B (Merck Serono SA) ; Jego, V (Merck Serono SA) ; von Richter, O (Merck KGaA) ; Ciardiello, F (Second University of Naples. Department of Experimental and Clinical Medicine) ; Universitat Autònoma de Barcelona
The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib. [...]
2015 - 10.1038/bjc.2015.144
British Journal of Cancer, Vol. 112 (June 2015) , p. 1874-1881  
4.
12 p, 5.3 MB Methylation of MGMT and ADAMTS14 in normal colon mucosa: biomarkers of a field defect for cancerization preferentially targeting elder African-Americans / Alonso, Sergio (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Dai, Yuichi (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Yamashita, Kentaro (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Horiuchi, Shina (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Dai, Tomoko (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Matsunaga, Akihiro (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Sánchez Muñoz, Rosa (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Bilbao Sieyro, Cristina (Instituto Canario de Investigación del Cáncer) ; Díaz Chico, Juan Carlos (Instituto Canario de Investigación del Cáncer) ; Chernov, Andrei V. (Sanford Burnham Prebys Medical Discovery Institute (Califòrnia)) ; Strongin, Alex Y. (Sanford Burnham Prebys Medical Discovery Institute (Califòrnia)) ; Perucho, Manuel (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer)
Somatic hypermethylation of the O6-methylguanine-DNA methyltransferase gene (MGMT) was previously associated with G > A transition mutations in KRAS and TP53 in colorectal cancer (CRC). We tested the association of MGMT methylation with G > A mutations in KRAS and TP53 in 261 CRCs. [...]
2015 - 10.18632/oncotarget.2852
Oncotarget, Vol. 6 Núm. 5 (february 2015)  
5.
27 p, 8.4 MB Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model / Álamo, Patricia (Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina) ; Gallardo Alcañiz, Alberto (Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina) ; Di Nicolantonio, Federica (Università degli studi di Torino. Dipartimento di Oncologia) ; Pavón Ribas, Miguel Ángel (Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina) ; Casanova, Isolda (Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina) ; Trias Folch, Manuel (Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina) ; Mangues i Bafalluy, Ma. Antònia (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya). Servei de Cirurgia General i Digestiva) ; Lopez-Pousa, Antonio (Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina) ; Villaverde Corrales, Antonio (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Vázquez Gómez, Esther (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Bardelli, Alberto (Università degli studi di Torino. Dipartimento di Oncologia) ; Céspedes, María Virtudes (Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina) ; Mangues, Ramón (Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina)
Although all KRas (protein that in humans is encoded by the KRas gene) point mutants are considered to have a similar prognostic capacity, their transformation and tumorigenic capacities vary widely. [...]
2015 - 10.1096/fj.14-262303
The FASEB journal, Vol. 29 Issue 2 (Feb. 2015) , p. 464-476  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.